In 2024, Xiamen Biopharmaceutical Port in Haicang secured approvals for 116 Class III medical devices, with an additional 47 Class III devices approved in Q1 2025. A total of 57 innovative and improved drug candidates have entered clinical trials, marking a flourishing phase of innovation following years of cultivation. Ranked 13th in comprehensive competitiveness in the 2024 National Biopharmaceutical Industrial Park Ranking released by China National Center for Biotechnology Development, the port has maintained a top-15 position for six consecutive years. Innovation remains the primary driver of biomedical advancement: while accelerating breakthroughs in core technologies, entities within the port are extending their innovation chains and building service platform matrices. Moving forward, Haicang will continue enhancing enabling platforms and optimizing its world-class business environment for biopharmaceutical industry growth.
